Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4846080 | 0.92 | MEN1 (0.41) | PARP1HSD17B10NR1H2ALDH1A1MEN1 | |
| SCHEMBL4836292 | 0.87 | HSD17B10 (0.39) | PARP1HSD17B10NR1H2NR1H3ALDH1A1 | |
| SCHEMBL4840180 | 0.84 | NR1H2 (0.40) | PARP1HSD17B10NR1H2NR1H3ALDH1A1 | |
| SCHEMBL28490941 | 0.84 | PARP1 (0.48) | PARP1HSD17B10NR1H2NR1H3ALDH1A1 | |
| SCHEMBL4837008 | 0.81 | PARP1 (0.36) | PARP1HSD17B10NR1H2NR1H3SMN1; SMN2 | |
| SCHEMBL1183970 | 0.81 | NR1H2 (0.46) | PARP1HSD17B10NR1H2NR1H3ALDH1A1 | |
| SCHEMBL30111484 | 0.81 | NR1H2 (0.46) | PARP1HSD17B10NR1H2NR1H3ALDH1A1 | |
| SCHEMBL4844498 | 0.81 | PARP1 (0.36) | PARP1HSD17B10NR1H2NR1H3ALDH1A1 | |
| SCHEMBL4843493 | 0.81 | PARP1 (0.37) | PARP1HSD17B10NR1H2NR1H3ATM | |
| SCHEMBL4836555 | 0.81 | NR1H2 (0.38) | PARP1HSD17B10NR1H2NR1H3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| EP-1546134-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014895-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | PARP1 2330/4885HSD17B10 1680/4885NR1H2 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.